Abstract
To investigate and validate the mechanism of LXTHF in the treatment of IHC through network pharmacology, molecular docking technology, and animal experiments. The overall methodology included the identification of the major active ingredients of LXTHF using the ultra-performance liquid chromatography (UPLC) technique. Subsequently, network pharmacology was utilized to analyze and predict the interaction between the corresponding targets of LXTHF and IHC. Furthermore, an ANIT-induced rat model was established, and the serum and liver tissues were collected to assess the hepatoprotective effects of LXTHF, and a serum untargeted metabolomics test was performed. Finally, the precision of the results was verified at the molecular level through molecular docking, immunohistochemistry, and RT-qPCR. There were 162 active ingredients and 213 targets associated with LXTHF-IHC that were detected. The animal experiments have shown that LXTHF reversed the levels of liver function indexes in the ANIT group, which markedly performed anti-inflammatory, hepatoprotective, and enzyme-lowering effects. Combining the results of network pharmacology and metabolomics, we found that LXTHF could scavenge free radicals, suppress oxidative stress, and regulate the levels of bile acid in the serum by participating in the methionine cycle. Our results preliminarily suggested that LXTHF has a favorable anticholestatic effect in the ANIT-induced rat model, and the methionine and cysteine metabolic pathway plays an important role in this process.
